193. プラダー・ウィリ症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
ACOMPLIA 20 mg film-coated tablets
Karolinska University Hospital
2008 - EUCTR2007-006305-25-SE Sweden;
ACTH
Nationwide Children's Hospital
2014 - NCT02368379 United States;
ARD-101
Aardvark Therapeutics, Inc.
2022 Phase 2 NCT05153434 United States;
AZP-531
Alize Pharma
2015 Phase 2 EUCTR2014-001670-34-FR France;Italy;Spain;
2015 Phase 2 EUCTR2014-001670-34-ES France;Italy;Spain;
2015 - EUCTR2014-001670-34-IT France;Italy;Spain;
Millendo Therapeutics SAS
2020 Phase 2;Phase 3 EUCTR2018-003062-13-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-NL Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-GB Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-ES Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-BE Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003062-13-IT Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Acylated and unacylated ghrelin dosages
University Hospital, Toulouse
2021 - NCT04768803 -
Anastrozole
Assistance Publique - Hôpitaux de Paris
2012 - NCT01520467 France;
B. lactis B94
University of Florida
2017 - NCT03277157 United States;
Biopsy
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Byetta
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
CBDV Compound
Montefiore Medical Center
2020 Phase 2 NCT03848481 United States;
Cannabidiol
Benuvia Therapeutics Inc.
2018 Phase 2 NCT02844933 United States;
Cannabidiol Oral Solution
Benuvia Therapeutics Inc.
2018 Phase 2 NCT03458416 United States;
Coenzyme Q10
The Hospital for Sick Children
2022 Phase 2 NCT03831425 Canada;
D.3.2 Product code where applicable13:
Millendo Therapeutics SAS
2019 Phase 2 EUCTR2018-003062-13-IT Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
DCCR
Essentialis, Inc.
2014 Phase 1/Phase 2 NCT02034071 United States;
Soleno Therapeutics UK Ltd.
2019 Phase 3 EUCTR2018-004216-22-GB United Kingdom;United States;
2019 Phase 3 EUCTR2018-004215-50-GB United Kingdom;United States;
Soleno Therapeutics, Inc.
2019 Phase 3 NCT04086810 -
2018 Phase 3 NCT03714373 United Kingdom;United States;
2018 Phase 3 NCT03440814 United Kingdom;United States;
DEXA, blood tests, H.G.P.O, osseous age.
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Diazoxide choline controlled-release tablet
Essentialis, Inc.
2017 Phase 2 NCT02893618 -
EU/1/06/362/003: 5µg (1 pen)
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
Eutropin
LG Life Sciences
2014 Phase 3 NCT02204163 Korea, Republic of;
Exenatide
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
Children's Hospital Los Angeles
2012 - NCT01444898 United States;
Garvan Institute of Medical Research
2007 - NCT00551343 Australia;
FE 992097
Ferring Pharmaceuticals
2014 Phase 2 NCT01968187 United States;
Fluimucil (acetylcysteine)
Dutch Growth Research Foundation
2021 Phase 2;Phase 3 EUCTR2019-000735-61-NL Netherlands;
Follow-up probiotic
Fundació Sant Joan de Déu
2021 Phase 1/Phase 2 NCT04685057 Spain;
Follow-up study of the treated cohort
University Hospital, Toulouse
2021 Phase 3 NCT05032326 France;
GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.
Dutch growth research foundation
2012 - EUCTR2011-001313-14-NL Netherlands;
GLWL-01
GLWL Research Inc.
2018 Phase 2 NCT03274856 Canada;United States;
Genotonorm Miniquick 0,
Fundació Parc Taulí
2017 Phase 4 EUCTR2017-002164-41-ES Spain;
Genotropin
Dutch Growth Foundation
2008 Phase 4 EUCTR2007-004716-31-NL Netherlands;
LG Life Sciences
2014 Phase 3 NCT02204163 Korea, Republic of;
Gold
Children's Hospital Affiliated to Medical College of Zhejiang University
2020 Phase 0 ChiCTR2000039618 China;
Growth hormone
Children's Hospital of Zhejiang University School of Medicine
2019 Phase 4 ChiCTR1900027464 China;
2019 - ChiCTR1900022809 China;
Corporacion Parc Tauli
2017 Phase 4 NCT03616509 Spain;
Growth hormone (Genotonorm® or Omnitrope®)
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Guanfacine extended release (GXR)
NYU Langone Health
2019 Phase 4 NCT04066088 United States;
H01BB02
Toulouse University Hospital
- Phase 3 EUCTR2021-000094-91-FR France;
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten
Oy Eli Lilly Finland Ab
2007 - EUCTR2007-000469-39-FI Finland;
INN Not yet proposed
Alize Pharma
2015 Phase 2 EUCTR2014-001670-34-FR France;Italy;Spain;
2015 Phase 2 EUCTR2014-001670-34-ES France;Italy;Spain;
2015 - EUCTR2014-001670-34-IT France;Italy;Spain;
Intranasal Oxytocin (IN-OXT)
Montefiore Medical Center
2018 Phase 2 NCT03197662 United States;
2015 Phase 2 NCT02629991 United States;
Intranasal oxytocin
University of Florida
2015 Phase 1 NCT02013258 United States;
Liraglutide
Novo Nordisk A/S
2015 Phase 3 NCT02527200 Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey;United States;
Vancouver General Hospital
2012 Phase 4 NCT01542242 Canada;
Livoletide
Millendo Therapeutics SAS
2020 Phase 2;Phase 3 EUCTR2018-003062-13-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-NL Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-GB Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-ES Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-BE Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2/Phase 3 NCT03790865 Australia;Belgium;France;Italy;Netherlands;Spain;United Kingdom;United States;
METOPROLOL SUCCINATE
Saniona A/S
2017 Phase 2 EUCTR2016-003694-18-CZ Czech Republic;Hungary;
2016 Phase 2 EUCTR2016-003694-18-HU Czech Republic;Hungary;
METOPROLOL SUCCINATE (PH. EUR.)
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Medical Air vs Oxygen
The Hospital for Sick Children
2016 Phase 4 NCT03031626 Canada;
Metoprololsuccinat Orion
Saniona A/S
2016 Phase 2 EUCTR2016-003694-18-HU Czech Republic;Hungary;
Metoprololsuccinat ”Orion”
Saniona A/S
2017 Phase 2 EUCTR2016-003694-18-CZ Czech Republic;Hungary;
Metyrapone
Nationwide Children's Hospital
2014 - NCT02368379 United States;
Norditropin SimpleXx
Karolinska University Hospital
2005 - NCT00372125 Denmark;Norway;Sweden;
Nutropin AQ
Children's Mercy Hospital Kansas City
2005 Phase 3 NCT00444964 United States;
OSSITOCINA
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
OT
University Hospital, Toulouse
2020 Phase 3 NCT04283578 France;
Octreotide
Duke University
2006 - NCT00399893 United States;
Oregon Health and Science University
2005 - NCT01613495 -
Oxytocin
Dutch Growth Research Foundation
2017 Phase 2;Phase 3 EUCTR2017-003423-30-NL Netherlands;
2016 Phase 3 EUCTR2016-003820-22-NL Netherlands;
2014 Phase 3 EUCTR2013-004134-15-NL Netherlands;
Toulouse University Hospital
- Phase 3 EUCTR2020-006161-11-FR France;
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
University Hospital, Toulouse
2017 - NCT03081832 France;
2016 - NCT03114371 France;
2013 Phase 1/Phase 2 NCT02205034 France;
2011 Phase 1/Phase 2 NCT01548521 France;
University of Florida
2017 Phase 1/Phase 2 NCT03245762 United States;
Oxytocin (OXT) continuous
University Hospital, Toulouse
2014 Phase 2/Phase 3 NCT02804373 France;
Physiological serum (Sodium chloride)
University Hospital, Toulouse
2009 Phase 2 NCT01038570 France;
Pitolisant oral tablets
Harmony Biosciences, LLC
2020 Phase 2 NCT04257929 United States;
Probiotic
Fundació Sant Joan de Déu
2018 - NCT03548480 Spain;
R05CB01
Dutch Growth Research Foundation
2021 Phase 2;Phase 3 EUCTR2019-000735-61-NL Netherlands;
RAD011
Radius Pharmaceuticals, Inc.
2022 Phase 2/Phase 3 NCT05098509 United States;
RECOMBINANT HUMAN GROWTH HORMON
Fundació Parc Taulí
2017 Phase 4 EUCTR2017-002164-41-ES Spain;
RM-493
Rhythm Pharmaceuticals, Inc.
2015 Phase 2 NCT02311673 United States;
Rapamycin
Peking Union Medical College Hospital
2021 Phase 0 ChiCTR2000040947 China;
Recombinant Human Growth Hormone (rhGH) Injection
GeneScience Pharmaceuticals Co., Ltd.
2018 Phase 3 NCT03554031 China;
Recombinant Somatropin
Corporacion Parc Tauli
2014 - NCT02205450 Spain;
RhGH
Cai Jinhua
2021 - ChiCTR2100046551 China;
Children's Hospital of Zhejiang University School of Medicine
2019 Phase 4 ChiCTR1900027464 China;
Rimonabant
Weill Medical College of Cornell University
2007 Phase 3 NCT00603109 United States;
Sandostatin LAR
University of British Columbia
2004 Phase 3 NCT00175305 Canada;
Saxenda
Novo Nordisk A/S
2016 Phase 3 EUCTR2014-004415-37-NL Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
2015 Phase 3 EUCTR2014-004415-37-IT Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
- Phase 3 EUCTR2014-004415-37-FR Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
Somatropin
Erasmus Medical Center
2020 Phase 3 NCT04484051 Australia;Netherlands;
Nagashima Masahito
2021 Phase 3 JPRN-jRCT2031200351 Japan;
Novo Nordisk A/S
2011 Phase 1 NCT01401244 United States;
2008 - NCT00705172 Denmark;Germany;Switzerland;
Somatropin - GH naïve pediatric cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Somatropin - GH treated cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Somatropin - adult cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Subcutaneous Beloranib in Suspension
Zafgen Inc.
2016 Phase 3 EUCTR2015-000660-33-BE Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-FR Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-ES Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 - EUCTR2015-000660-33-SE Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Syntocinon
Centre Hospitalier de Toulouse
2014 Phase 3 EUCTR2013-004437-33-FR France;
- Phase 2 EUCTR2010-022370-14-FR France;
University Hospital of Toulouse
2016 Phase 3 EUCTR2016-003273-18-FR France;
Syntocinon nasal spray
Dutch Growth Research Foundation
2017 Phase 2;Phase 3 EUCTR2017-003423-30-NL Netherlands;
2016 Phase 3 EUCTR2016-003820-22-NL Netherlands;
2014 Phase 3 EUCTR2013-004134-15-NL Netherlands;
Syntocinon®/- Spray
University Hospital, Toulouse
2009 Phase 2 NCT01038570 France;
TESOFENSINE CITRATE
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Tesofensine/Metoprolol
Saniona
2017 Phase 2 NCT03149445 Czechia;
Tesomet
Saniona
2021 Phase 2 NCT05198362 United States;
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Topiramate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 3 EUCTR2011-003432-32-FR France;
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT02810483 France;
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2002 - NCT00065923 United States;
ZGN-440
Zafgen Inc.
2016 Phase 3 EUCTR2015-000660-33-BE Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-FR Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-ES Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 - EUCTR2015-000660-33-SE Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
ZGN-440 for Injectable Suspension
Zafgen, Inc.
2014 Phase 3 NCT02179151 United States;
ZGN-440 for injectable suspension
Zafgen, Inc.
2013 Phase 2 NCT01818921 United States;
ZGN-440 sterile diluent
Zafgen, Inc.
2013 Phase 2 NCT01818921 United States;
intranasal carbetocin
Levo Therapeutics, Inc.
2018 Phase 3 NCT03649477 Australia;Canada;United States;
Karolinska University Hospital
2008 - EUCTR2007-006305-25-SE Sweden;
ACTH
Nationwide Children's Hospital
2014 - NCT02368379 United States;
ARD-101
Aardvark Therapeutics, Inc.
2022 Phase 2 NCT05153434 United States;
AZP-531
Alize Pharma
2015 Phase 2 EUCTR2014-001670-34-FR France;Italy;Spain;
2015 Phase 2 EUCTR2014-001670-34-ES France;Italy;Spain;
2015 - EUCTR2014-001670-34-IT France;Italy;Spain;
Millendo Therapeutics SAS
2020 Phase 2;Phase 3 EUCTR2018-003062-13-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-NL Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-GB Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-ES Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-BE Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003062-13-IT Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Acylated and unacylated ghrelin dosages
University Hospital, Toulouse
2021 - NCT04768803 -
Anastrozole
Assistance Publique - Hôpitaux de Paris
2012 - NCT01520467 France;
B. lactis B94
University of Florida
2017 - NCT03277157 United States;
Biopsy
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Byetta
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
CBDV Compound
Montefiore Medical Center
2020 Phase 2 NCT03848481 United States;
Cannabidiol
Benuvia Therapeutics Inc.
2018 Phase 2 NCT02844933 United States;
Cannabidiol Oral Solution
Benuvia Therapeutics Inc.
2018 Phase 2 NCT03458416 United States;
Coenzyme Q10
The Hospital for Sick Children
2022 Phase 2 NCT03831425 Canada;
D.3.2 Product code where applicable13:
Millendo Therapeutics SAS
2019 Phase 2 EUCTR2018-003062-13-IT Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
DCCR
Essentialis, Inc.
2014 Phase 1/Phase 2 NCT02034071 United States;
Soleno Therapeutics UK Ltd.
2019 Phase 3 EUCTR2018-004216-22-GB United Kingdom;United States;
2019 Phase 3 EUCTR2018-004215-50-GB United Kingdom;United States;
Soleno Therapeutics, Inc.
2019 Phase 3 NCT04086810 -
2018 Phase 3 NCT03714373 United Kingdom;United States;
2018 Phase 3 NCT03440814 United Kingdom;United States;
DEXA, blood tests, H.G.P.O, osseous age.
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Diazoxide choline controlled-release tablet
Essentialis, Inc.
2017 Phase 2 NCT02893618 -
EU/1/06/362/003: 5µg (1 pen)
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
Eutropin
LG Life Sciences
2014 Phase 3 NCT02204163 Korea, Republic of;
Exenatide
Aintree University Hospital NHS Foundation Trust
2011 - EUCTR2010-023179-25-GB United Kingdom;
Children's Hospital Los Angeles
2012 - NCT01444898 United States;
Garvan Institute of Medical Research
2007 - NCT00551343 Australia;
FE 992097
Ferring Pharmaceuticals
2014 Phase 2 NCT01968187 United States;
Fluimucil (acetylcysteine)
Dutch Growth Research Foundation
2021 Phase 2;Phase 3 EUCTR2019-000735-61-NL Netherlands;
Follow-up probiotic
Fundació Sant Joan de Déu
2021 Phase 1/Phase 2 NCT04685057 Spain;
Follow-up study of the treated cohort
University Hospital, Toulouse
2021 Phase 3 NCT05032326 France;
GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.
Dutch growth research foundation
2012 - EUCTR2011-001313-14-NL Netherlands;
GLWL-01
GLWL Research Inc.
2018 Phase 2 NCT03274856 Canada;United States;
Genotonorm Miniquick 0,
Fundació Parc Taulí
2017 Phase 4 EUCTR2017-002164-41-ES Spain;
Genotropin
Dutch Growth Foundation
2008 Phase 4 EUCTR2007-004716-31-NL Netherlands;
LG Life Sciences
2014 Phase 3 NCT02204163 Korea, Republic of;
Gold
Children's Hospital Affiliated to Medical College of Zhejiang University
2020 Phase 0 ChiCTR2000039618 China;
Growth hormone
Children's Hospital of Zhejiang University School of Medicine
2019 Phase 4 ChiCTR1900027464 China;
2019 - ChiCTR1900022809 China;
Corporacion Parc Tauli
2017 Phase 4 NCT03616509 Spain;
Growth hormone (Genotonorm® or Omnitrope®)
University Hospital, Toulouse
2009 Phase 4 NCT01298180 France;
Guanfacine extended release (GXR)
NYU Langone Health
2019 Phase 4 NCT04066088 United States;
H01BB02
Toulouse University Hospital
- Phase 3 EUCTR2021-000094-91-FR France;
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten
Oy Eli Lilly Finland Ab
2007 - EUCTR2007-000469-39-FI Finland;
INN Not yet proposed
Alize Pharma
2015 Phase 2 EUCTR2014-001670-34-FR France;Italy;Spain;
2015 Phase 2 EUCTR2014-001670-34-ES France;Italy;Spain;
2015 - EUCTR2014-001670-34-IT France;Italy;Spain;
Intranasal Oxytocin (IN-OXT)
Montefiore Medical Center
2018 Phase 2 NCT03197662 United States;
2015 Phase 2 NCT02629991 United States;
Intranasal oxytocin
University of Florida
2015 Phase 1 NCT02013258 United States;
Liraglutide
Novo Nordisk A/S
2015 Phase 3 NCT02527200 Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey;United States;
Vancouver General Hospital
2012 Phase 4 NCT01542242 Canada;
Livoletide
Millendo Therapeutics SAS
2020 Phase 2;Phase 3 EUCTR2018-003062-13-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-NL Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-GB Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-ES Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-003062-13-BE Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2/Phase 3 NCT03790865 Australia;Belgium;France;Italy;Netherlands;Spain;United Kingdom;United States;
METOPROLOL SUCCINATE
Saniona A/S
2017 Phase 2 EUCTR2016-003694-18-CZ Czech Republic;Hungary;
2016 Phase 2 EUCTR2016-003694-18-HU Czech Republic;Hungary;
METOPROLOL SUCCINATE (PH. EUR.)
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Medical Air vs Oxygen
The Hospital for Sick Children
2016 Phase 4 NCT03031626 Canada;
Metoprololsuccinat Orion
Saniona A/S
2016 Phase 2 EUCTR2016-003694-18-HU Czech Republic;Hungary;
Metoprololsuccinat ”Orion”
Saniona A/S
2017 Phase 2 EUCTR2016-003694-18-CZ Czech Republic;Hungary;
Metyrapone
Nationwide Children's Hospital
2014 - NCT02368379 United States;
Norditropin SimpleXx
Karolinska University Hospital
2005 - NCT00372125 Denmark;Norway;Sweden;
Nutropin AQ
Children's Mercy Hospital Kansas City
2005 Phase 3 NCT00444964 United States;
OSSITOCINA
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
OT
University Hospital, Toulouse
2020 Phase 3 NCT04283578 France;
Octreotide
Duke University
2006 - NCT00399893 United States;
Oregon Health and Science University
2005 - NCT01613495 -
Oxytocin
Dutch Growth Research Foundation
2017 Phase 2;Phase 3 EUCTR2017-003423-30-NL Netherlands;
2016 Phase 3 EUCTR2016-003820-22-NL Netherlands;
2014 Phase 3 EUCTR2013-004134-15-NL Netherlands;
Toulouse University Hospital
- Phase 3 EUCTR2020-006161-11-FR France;
University Hospital Toulouse
- Phase 3 EUCTR2019-002385-12-IT Belgium;France;Germany;Italy;Netherlands;
University Hospital, Toulouse
2017 - NCT03081832 France;
2016 - NCT03114371 France;
2013 Phase 1/Phase 2 NCT02205034 France;
2011 Phase 1/Phase 2 NCT01548521 France;
University of Florida
2017 Phase 1/Phase 2 NCT03245762 United States;
Oxytocin (OXT) continuous
University Hospital, Toulouse
2014 Phase 2/Phase 3 NCT02804373 France;
Physiological serum (Sodium chloride)
University Hospital, Toulouse
2009 Phase 2 NCT01038570 France;
Pitolisant oral tablets
Harmony Biosciences, LLC
2020 Phase 2 NCT04257929 United States;
Probiotic
Fundació Sant Joan de Déu
2018 - NCT03548480 Spain;
R05CB01
Dutch Growth Research Foundation
2021 Phase 2;Phase 3 EUCTR2019-000735-61-NL Netherlands;
RAD011
Radius Pharmaceuticals, Inc.
2022 Phase 2/Phase 3 NCT05098509 United States;
RECOMBINANT HUMAN GROWTH HORMON
Fundació Parc Taulí
2017 Phase 4 EUCTR2017-002164-41-ES Spain;
RM-493
Rhythm Pharmaceuticals, Inc.
2015 Phase 2 NCT02311673 United States;
Rapamycin
Peking Union Medical College Hospital
2021 Phase 0 ChiCTR2000040947 China;
Recombinant Human Growth Hormone (rhGH) Injection
GeneScience Pharmaceuticals Co., Ltd.
2018 Phase 3 NCT03554031 China;
Recombinant Somatropin
Corporacion Parc Tauli
2014 - NCT02205450 Spain;
RhGH
Cai Jinhua
2021 - ChiCTR2100046551 China;
Children's Hospital of Zhejiang University School of Medicine
2019 Phase 4 ChiCTR1900027464 China;
Rimonabant
Weill Medical College of Cornell University
2007 Phase 3 NCT00603109 United States;
Sandostatin LAR
University of British Columbia
2004 Phase 3 NCT00175305 Canada;
Saxenda
Novo Nordisk A/S
2016 Phase 3 EUCTR2014-004415-37-NL Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
2015 Phase 3 EUCTR2014-004415-37-IT Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
- Phase 3 EUCTR2014-004415-37-FR Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
Somatropin
Erasmus Medical Center
2020 Phase 3 NCT04484051 Australia;Netherlands;
Nagashima Masahito
2021 Phase 3 JPRN-jRCT2031200351 Japan;
Novo Nordisk A/S
2011 Phase 1 NCT01401244 United States;
2008 - NCT00705172 Denmark;Germany;Switzerland;
Somatropin - GH naïve pediatric cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Somatropin - GH treated cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Somatropin - adult cohort
Pfizer
2021 Phase 3 NCT04697381 Japan;
Subcutaneous Beloranib in Suspension
Zafgen Inc.
2016 Phase 3 EUCTR2015-000660-33-BE Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-FR Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-ES Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 - EUCTR2015-000660-33-SE Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Syntocinon
Centre Hospitalier de Toulouse
2014 Phase 3 EUCTR2013-004437-33-FR France;
- Phase 2 EUCTR2010-022370-14-FR France;
University Hospital of Toulouse
2016 Phase 3 EUCTR2016-003273-18-FR France;
Syntocinon nasal spray
Dutch Growth Research Foundation
2017 Phase 2;Phase 3 EUCTR2017-003423-30-NL Netherlands;
2016 Phase 3 EUCTR2016-003820-22-NL Netherlands;
2014 Phase 3 EUCTR2013-004134-15-NL Netherlands;
Syntocinon®/- Spray
University Hospital, Toulouse
2009 Phase 2 NCT01038570 France;
TESOFENSINE CITRATE
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Tesofensine/Metoprolol
Saniona
2017 Phase 2 NCT03149445 Czechia;
Tesomet
Saniona
2021 Phase 2 NCT05198362 United States;
Saniona A/S
2022 Phase 2 EUCTR2021-000127-12-SE Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Topiramate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 3 EUCTR2011-003432-32-FR France;
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT02810483 France;
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2002 - NCT00065923 United States;
ZGN-440
Zafgen Inc.
2016 Phase 3 EUCTR2015-000660-33-BE Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-FR Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 Phase 3 EUCTR2015-000660-33-ES Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
2015 - EUCTR2015-000660-33-SE Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
ZGN-440 for Injectable Suspension
Zafgen, Inc.
2014 Phase 3 NCT02179151 United States;
ZGN-440 for injectable suspension
Zafgen, Inc.
2013 Phase 2 NCT01818921 United States;
ZGN-440 sterile diluent
Zafgen, Inc.
2013 Phase 2 NCT01818921 United States;
intranasal carbetocin
Levo Therapeutics, Inc.
2018 Phase 3 NCT03649477 Australia;Canada;United States;